VivoSim Labs

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

VivoSim Labs Inc

Health Care

Press Releases

General

VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market

VivoSim Presents Best-in-Class Liver Toxicology Prediction  Results at Digestive Disease Week Conference

News

VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference

ONVO

VIVS

Aditxt

Apollomics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

180 Life Sciences

Azitra

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Galecto

GRI Bio

Mustang Bio

Moleculin Biotech

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Oragenics

Palisade Bio

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Polyrizon

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

SILO Pharma

Soligenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tharimmune

Theriva Biologics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

ZyVersa Therapeutics, Inc. - Common Stock

Comments

VivoSim Labs

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell